+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

ERCC1 and beta tubulin class III (BT-III) expression by quantitative immunofluorescence (IF) in the responder and non-responder group of patients with advanced non-small-cell lung cancer after 2 cycles of cisplatin (P) and vinorelbine (Vn) chemotherapy



ERCC1 and beta tubulin class III (BT-III) expression by quantitative immunofluorescence (IF) in the responder and non-responder group of patients with advanced non-small-cell lung cancer after 2 cycles of cisplatin (P) and vinorelbine (Vn) chemotherapy



Journal of Clinical Oncology 26(15_Suppl): 19065-19065



NlmCategory="UNASSIGNED">19065 Background: Recent data indicates that ERCC1 expression correlates with platinum responsiveness in adjuvant therapy and in stage IV disease. BT-III expression has been correlated to sensitivity to anti-tubulin agents. We investigated whether ERCC1 and BT-III expression level is correlated with clinical responsiveness in the patients treated with PVn chemotherapy utilizing a novel quantifiable IF method to assess ERCC1 and BT-III expression. We retrospectively studied 36 patients who received the first line chemotherapy of P 60 mg/m2 D1 and Vn 25 mg/m2 D1, D8 q 3 weeks and were categorized into 2 groups of responder(R) and non-responder(nR) (defined as more than partial response and as stable disease or progressive disease, respectively, after 2 cycles of chemotherapy). Paraffin embedded tumor specimens were analyzed by quantitative IF staining for ERCC1 and BT-III expression using anti-ERCC1 (clone 8F1, GeneTex) and anti-beta tubulin class III (clone SDL.3D10, Sigma-Aldrich) respectively. The intensity of IF was measured quantitatively with a digitalized microscopy system (expression level from 0 to 10) and expressed as the mean of the average fluorescence per pixel. Among 36 patients who received the first line PVn chemotherapy 2 cycles, R was 19 and nR 13 (RR 59%). 32 tumor specimens were available for IF staining, but 26 cases were analyzable by quantitative IF staining (excluded 3 cases each from R and nR). ERCC1 expression in R ranged from 1 to 8 (mean 3.17, SD 1.76) and that in nR ranged from 1.5 to 10 (mean 4.94, SD 2.55, p=0.063). BT-III expression in R ranged from 1 to 9.7 (mean 3.87, SD 2.20) and that in nR ranged from 0.5 to 9.7 (mean 3.08, SD 3.02, p=0.474). R/nR ratio in high(+) ERCC1/high(+)BT-III was 3/1, +/low(-) 3/5, -/+ 5/2, -/- 4/3. Clinical responsiveness of cisplatin and vinorelbine chemotherapy in the patients with advanced non-small-cell lung cancer was good and we observed a tendency toward correlation between ERCC1 expression and clinical responsiveness but poor correlation in terms of BT-III expression within the limitations of small sample size. No significant financial relationships to disclose.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057676567

Download citation: RISBibTeXText

PMID: 27947892


Related references

Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study JBR.10. Journal of Clinical Oncology 24(18_Suppl): 7051-7051, 2016

Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clinical Cancer Research 13(3): 994-999, 2007

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer ChemoTherapy and Pharmacology 64(3): 565-573, 2009

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clinical Cancer Research 11(15): 5481-5486, 2005

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64(3): 326-333, 2008

A randomized phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_Suppl): Lba7024-Lba7024, 2016

Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. Journal of Clinical Oncology 26(11): 1886-1892, 2008

Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathology International 59(12): 863-867, 2010

Expression of ERCC1 and class III ß-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy. International Journal of Biological Markers 25(3): 141-149, 2011

High expression levels of class III β-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy. Oncology Letters 6(1): 220-226, 2013

Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC). Lung Cancer 47(3): 395-404, 2005

Cisplatin/gemcitabine vs cisplatin/gemcitabine/vinorelbine vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine in advanced non-small cell lung cancer Final results of a Spanish lung cancer group phase III trial. European Journal of Cancer 37(Suppl. 6): S28, 2001

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 74(2): 310-317, 2012

Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer. Lung Cancer 21(3): 213-220, 1998

NCombination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: A multicenter phase Ii study of the Greek Cooperative Group for Lung Cancer. Lung Cancer 21(3): 213-220, 1998